SAN DIEGO, July 28, 2021–(Small business WIRE)–Robbins Geller Rudman & Dowd LLP announces that a course motion lawsuit has been submitted on behalf of purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) popular stock concerning November 16, 2020 and March 22, 2021, inclusive (the “Class Period of time”). The Frequency Therapeutics class motion lawsuit charges Frequency Therapeutics and particular of its executives with violations of the Securities Exchange Act of 1934. The Frequency Therapeutics course action lawsuit (Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933) was filed in the District of Massachusetts and is assigned to Decide William G. Youthful. A related lawsuit, captioned Hingston v. Frequency Therapeutics, Inc., No. 21-cv-11040, is also pending in the District of Massachusetts.
If you suffered significant losses and would like to provide as guide plaintiff of the Frequency Therapeutics class action lawsuit, remember to offer your facts by clicking right here. You can also call legal professional J.C. Sanchez of Robbins Geller by contacting 800/449-4900 or through e-mail at [email protected]. Lead plaintiff motions for the Frequency Therapeutics class action lawsuit should be filed with the court no later on than August 2, 2021.
Circumstance ALLEGATIONS: The Frequency Therapeutics class motion lawsuit alleges that, shortly following launching the Period Forex-322 2a trial, Frequency Therapeutics and its Main Government Officer, defendant David L. Lucchino, figured out that the Stage 2a demo effects uncovered no discernable variance among Fx-322 and the placebo. The Frequency Therapeutics course motion lawsuit additional alleges that, while Frequency Therapeutics’ stock rate remained artificially inflated, defendant Lucchino marketed about 350,000 Frequency Therapeutics shares, pocketing more than $10.5 million.
On March 23, 2021, Frequency Therapeutics disclosed deeply disappointing interim Period 2a results, revealing that subjects with moderate to reasonable significant sensorineural hearing decline did not exhibit advancements in hearing steps versus placebo. On this information, Frequency Therapeutics’ inventory rate fell by nearly 78%, harmful traders.
THE Guide PLAINTIFF System: The Non-public Securities Litigation Reform Act of 1995 permits any trader who bought Frequency Therapeutics common stock in the course of the Course Time period to look for appointment as lead plaintiff in the Frequency Therapeutics class action lawsuit. A direct plaintiff is frequently the movant with the greatest money fascination in the relief sought by the putative course who is also regular and suitable of the putative course. A direct plaintiff functions on behalf of all other class customers in directing the Frequency Therapeutics course action lawsuit. The lead plaintiff can find a regulation firm of its selection to litigate the Frequency Therapeutics class action lawsuit. An investor’s capability to share in any potential long run recovery of the Frequency Therapeutics class motion lawsuit is not dependent upon serving as guide plaintiff.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 legal professionals in 9 places of work nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. legislation organization representing buyers in securities course actions. Robbins Geller lawyers have received quite a few of the premier shareholder recoveries in historical past, like the major securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Motion Products and services Leading 50 Report rated Robbins Geller to start with for recovering $1.6 billion for traders previous 12 months, much more than double the total recovered by any other securities plaintiffs’ company. Please take a look at https://www.rgrdlaw.com/firm.html for much more information and facts.
Legal professional advertising.
Earlier outcomes do not promise long run outcomes.
Services may possibly be done by attorneys in any of our offices.
Check out supply variation on businesswire.com: https://www.businesswire.com/information/residence/20210728005114/en/
Contacts
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]
